Business Context and Reporting Period
This Form 8-K is filed by Croff Enterprises, Inc. (not Therapeuticsmd, Inc. as indicated in metadata) on November 17, 2005. The report addresses a revision to the Form 10-Q for the quarter ended September 30, 2005.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses solely on the accounting adjustment regarding a "plug and abandonment expense" calculated in compliance with FAS 143.
Material Changes
- The company determined to file an amended 10-Q to include the aforementioned plug and abandonment expense.
- Management does not believe the changes resulting from the revised schedule are material to the financial statements, though they may result in some changes to the statements and Footnote 1.
Guidance, Outlook, and Risks
The amended 10-Q is expected to be filed within ten business days of this report. The decision to revise the filing was discussed with the registrant's independent accountants, the audit committee chairman, the President, and legal counsel. No specific guidance or new risk factors were disclosed in this text.
Investor Verification Checklist
- Verify the correct registrant name is Croff Enterprises, Inc., not Therapeuticsmd, Inc.
- Monitor the filing of the amended 10-Q within the next ten business days for the specific impact of the FAS 143 expense.
- Review Footnote 1 of the amended financial statements for details on the plug and abandonment expense.